Ranked by reported Q3 2025 13F market value
Share of total reported institutional value in CLSD held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | Carmignac Gestion | 101K | $399K | -93.3% | 1.921% | 0.01% |
| 2 | Apollon Wealth Management, LLC | 12K | $47K | — | 0.225% | 0.00% |
| 3 | ADVISOR GROUP HOLDINGS, INC. | 3K | $900 | +150.0% | 0.048% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in CLSD — a direct measure of their conviction.
Filings activity in CLSD during Q3 2025, grouped by how each filer changed its position.
No institutions added to their position this quarter.
8 quarters of 13F filings · Δ columns show change vs prior quarter
| Quarter | Inst. Holders | Δ Holders | Ownership % | Δ Ownership | Total 13F Value | Δ Value |
|---|---|---|---|---|---|---|
| Q3 2025 | 3 | 93% | 20.83% | 179.16 pp | $0M | 94% |
| Q2 2025 | 46 | +2.2% | 199.99% | +0.00 pp | $7M | 11% |
| Q1 2025 | 45 | +0.0% | 199.99% | +0.00 pp | $8M | 12% |
| Q4 2024 | 45 | 6.3% | 199.99% | +0.00 pp | $9M | 30% |
| Q3 2024 | 48 | 2.0% | 199.99% | +0.00 pp | $13M | 28% |
| Q2 2024 | 49 | 5.8% | 199.99% | +0.00 pp | $18M | 22% |
| Q1 2024 | 52 | 1.9% | 199.99% | +0.00 pp | $23M | 77% |
| Q2 2021 | 53 | — | 199.99% | — | $98M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying CLSD stock.
Based on Q3 2025 13F filings, institutional ownership of Clearside Biomedical, Inc. stands at 20.8%, held across 3 reporting institutions.
Carmignac Gestion is the largest reported institutional holder of CLSD, with approximately 100,556 shares worth $0.00B as of Q3 2025.
No marquee "smart money" managers (Berkshire, Burry, ARK, Tiger Global, Pershing Square, Baupost, etc.) currently appear among the top 25 institutional holders of CLSD.
Our composite Smart Money Score for CLSD is 5 out of 100 (Heavy Distribution). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
1 institutions opened new positions in CLSD during Q3 2025, while 44 fully exited. 0 added to existing positions and 2 trimmed.
CLSD institutional ownership fell by 179.16 percentage points quarter-over-quarter, with a net change of -43 holders.
The top 10 institutions account for 100.0% of all reported 13F value in CLSD, and the top 25 account for 100.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Clearside Biomedical, Inc. (CLSD) Institutional Ownership